SciELO - Scientific Electronic Library Online

 
vol.11 número1Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, Tanzania índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • En proceso de indezaciónSimilares en Google

Compartir


African Journal of Laboratory Medicine

versión On-line ISSN 2225-2010
versión impresa ISSN 2225-2002

Resumen

HODKINSON, Katherine E.; BOUWER, Nikki  y  VAUGHAN, Jenifer. South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook. Afr. J. Lab. Med. [online]. 2022, vol.11, n.1, pp.1-7. ISSN 2225-2010.  http://dx.doi.org/10.4102/ajlm.v11i1.1578.

BACKGROUND: Chronic myeloid leukaemia (CML) is a haematological malignancy characterised by the translocation t(9;22)(q34;q11.2), resulting in a constitutively active tyrosine kinase. Globally, overall survival of blast crisis phase (BC) CML is one year. Newer tyrosine kinase inhibitors and allogeneic stem cell transplantation offer remission; however, refractory and relapsed disease remain the biggest challenges. OBJECTIVE: In South Africa, literature is lacking on BC-CML. This study aimed to determine the disease characteristics and overall survival in South Africa. METHODS: This retrospective, laboratory-based study reviewed all new BC-CML diagnoses via flow cytometry at Charlotte Maxeke Johannesburg Academic Hospital in Johannesburg, South Africa, between April 2016 and October 2019. BC-CML was defined as the presence of > 20% blasts with a CML history or the BCR-ABL1 fusion gene (p210/p190) in the appropriate clinical or pathological context. Survival outcomes were inferred from clinical and laboratory data. RESULTS: Twenty-two new cases of BC-CML were diagnosed (median age: 34 years). There were 20 (91%) cases with the fusion transcripts p210 and two (9%) cases with p190 BCRABL1. For blast lineage, 14 cases were myeloid (63.6%), six were lymphoid (27.3%), and two were ambiguous (9.1%). There was a 72.7% mortality (16 cases); sepsis, refractory and relapsed disease were the major causes. Patients who achieved remission had lower blast percentages, simple karyotypes, and a trend towards higher white cell and platelet counts at presentation. CONCLUSION: Optimised management of early-stage CML, prevention and aggressive management of sepsis, with advocation for newer therapies are needed to improve the overall survival of BC-CML in South Africa

Palabras clave : chronic myeloid leukaemia; blast phase; major molecular route abnormalities; South Africa; p210 BCRABL1 fusion transcript; p190 BCRABL1 fusion transcript; responses by quantitative reverse transcriptase-polymerase chain reaction; karyotype.

        · texto en Inglés     · Inglés ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons